NasdaqGM - Delayed Quote USD

Esperion Therapeutics, Inc. (ESPR)

1.8700 +0.0300 (+1.63%)
At close: April 18 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Sheldon L. Koenig President, CEO & Director 1.28M -- 1966
Mr. Benjamin Halladay M.B.A. Chief Financial Officer -- -- 1986
Mr. Glenn P. Brame Chief Technical Operations Officer -- -- 1958

Esperion Therapeutics, Inc.

3891 Ranchero Drive
Suite 150
Ann Arbor, MI 48108
United States
734 887 3903 https://www.esperion.com
Sector: 
Healthcare
Full Time Employees: 
240

Description

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Corporate Governance

Esperion Therapeutics, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 7. The pillar scores are Audit: 4; Board: 5; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
Esperion Therapeutics, Inc. Earnings Call

Related Tickers

AQST Aquestive Therapeutics, Inc.
4.5000
+14.80%
 
ITCI Intra-Cellular Therapies, Inc.
72.00
-6.12%
 
AVDL Avadel Pharmaceuticals plc
17.38
-3.39%
 
OPTN OptiNose, Inc.
0.9277
-9.05%
 
FLGC Flora Growth Corp.
1.6800
-6.15%
 
SBFM Sunshine Biopharma, Inc.
3.3200
-12.63%
 
EOLS Evolus, Inc.
11.56
-0.69%
 
DERM Journey Medical Corporation
3.5800
-7.25%
 
DVAX Dynavax Technologies Corporation
11.34
-0.79%
 
ANIP ANI Pharmaceuticals, Inc.
64.58
-1.37%